A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses

Accumulating evidence suggests that increasing doses of rifampicin may shorten tuberculosis treatment. The PanACEA HIGHRIF1 trial assessed safety, pharmacokinetics, and antimycobacterial activity of rifampicin at doses up to 40 mg/kg. Eighty‐three pulmonary tuberculosis patients received 10, 20, 25,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacol Ther
Egile Nagusiak: Svensson, Robin J., Aarnoutse, Rob E., Diacon, Andreas H., Dawson, Rodney, Gillespie, Stephen H., Boeree, Martin J., Simonsson, Ulrika S.H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2017
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5888114/
https://ncbi.nlm.nih.gov/pubmed/28653479
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.778
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak